Endocrine Abstracts

The aims of the study were to analyze the relationship among insulin resistance, obesity, dysglycemia, dyslipidemia and to evaluate the role of common variants in candidate genes for their ability to predict the metabolic syndrome and cardio-metabolic risk factors.

Subjects and methods: 752 non-diabetic individuals (190 males and 562 females; age 35.05+4.47 years, BMI 26.72+5.92 kg/m²) participating in the study were genotyped for variants in peroxisome proliferator-activated receptor gamma (PPAR-γ2 Pro12Ala) and in adiponectin (ADIPOQ 45T>G; 276C>T) genes. Fasting blood sample was examined: lipids (total cholesterol, HDL-C, LDL-C, TAG), adiponectin (Adp), insulin; HOMA-IR was calculated. Regression analyses were used to find the associations of single nucleotide polymorphisms with cardio-metabolic risk factors.

Results: We found higher frequency of abdominal obesity in females, but frequency of lipid disorders, prediabetes, arterial hypertensive and insulin resistance was higher in males.

The frequency of SNPs PPAR-γ Pro12Ala, ADIPOQ +45T>G (rs2241766), and +276G>T (rs 1501299) in the whole study population (n=752) and in the obesity subjects (n=368) is comparable (0.158 and 152; 0.064 and 0.058; 0.256 and 0.276, respectively).

In men T allele ADIPOQ rs 1501299 is consistently associated with obesity (P=0.002), abdominal obesity (P=0.04), prandial hyperglycemia (P=0.002); G allele ADIPOQ rs 1501299 plays a protective role for HDL cholesterol level (P=0.047).

In women the PPAR-γ2 Ala12 variant plays a protective role in hypercholesterolemia (P=0.01). T allele ADIPOQ rs2241766 is significantly associated with reduced risk of obesity (P=0.004).

Conclusion: The allelic variation of the genes encoding adiponectin and PPAR-γ is gender-dependently associated with obesity and cardio-metabolic risk factors.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.